Furthermore, higher expression levels of ATF3, PPP1R15A, PPP2R5B, DDIT3, and BCL10 are associated with better prognosis in HER2+-BC patients, suggesting an overall tumor-suppressive role of the UPR-driven signaling cascade (Fig. S2F). Here, ERBB2 is linked to breast cancer.